Search results
Results from the WOW.Com Content Network
A 2016 Cochrane review (updated in 2021) found little difference in benefit between hydromorphone and other opioids for cancer pain. [10] Common side effects include dizziness, sleepiness, nausea, itchiness, and constipation. [7] Serious side effects may include abuse, low blood pressure, seizures, respiratory depression, and serotonin syndrome ...
Most of the adverse effects of Wellbutrin are mild and transient, although a small percentage of people who use this medication experience more severe or longer-lasting side effects. Common side ...
Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA). [5] It is used in the treatment of various conditions, most notably obsessive–compulsive disorder but also many other disorders, including hyperacusis, panic disorder, major depressive disorder, trichotillomania, [6] body dysmorphic disorder [7] [8] [9] and chronic pain. [5]
Oxymorphone (sold under the brand names Numorphan and Opana among others) is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. [6]
Vertex Pharmaceuticals is trumpeting the results of clinical trials indicating that VX-548, its new, non-opioid analgesic, is effective at relieving post-surgical pain. While there is nothing ...
Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression. [11] [12] Its effects may take up to four weeks but can also manifest as early as one to two weeks. [12] [13] It is often used in cases of depression complicated by anxiety or insomnia.
The drug is also under investigation as an antidepressant and for the treatment of neuropathic pain. It is related in chemical structure to venlafaxine. Due to being an opioid, there is risk of abuse and addiction, but it does have less abuse potential, respiratory depression, and constipation compared to other opioids (hydrocodone, oxycodone ...
There has been much debate as to whether reboxetine is more efficacious than placebo in the treatment of depression. According to a 2009 meta-analysis of 12 second-generation antidepressants, reboxetine was no more effective than placebo, and was "significantly less" effective and less acceptable than the other drugs in treating the acute-phase of adults with unipolar major depression.